Journal of Clinical Oncology, Vol 20, Issue 8
(April), 2002: 2150-2156
© 2002 American Society for Clinical Oncology
High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study
By F. Fagioli,
M. Aglietta,
A. Tienghi,
S. Ferrari,
A. Brach del Prever,
E. Vassallo,
A. Palmero,
E. Biasin,
G. Bacci,
P. Picci,
E. Madon
From the Department of Pediatrics, University of Turin; Department of Clinical Oncology, Ordine Mauriziano–Institute for Cancer Research and Treatment, Turin; Department of Oncology, Ospedale S. Maria delle Croci, Ravenna; and Department of Chemotherapy, Department of Musculoskeletal Tumors, Istituto Ortopedico Rizzoli, Bologna, Italy.
Address reprint requests to Franca Fagioli, MD, Department of Pediatrics, University of Turin, Piazza Polonia 94, 10126 Turin, Italy; email: fagioli{at}pediatria.unito.it
PURPOSE: To study the feasibility and activity of two courses of high-dose chemotherapy (HDCT) in patients with osteosarcoma in metastatic relapse.
PATIENTS AND METHODS: Patients with high-grade osteosarcoma in metastatic relapse (multiple metastases or solitary metastasis at intervals of less than 30 months) were eligible for study. High-dose chemotherapy consisted of carboplatin and etoposide followed by stem-cell rescue. A second course was planned 4 to 6 weeks after the first. Surgery was performed before or after HDCT.
RESULTS: Thirty-two patients were enrolled onto the study. At the end of the treatment, 25 patients were in complete remission (CR), six were alive with disease progression, and one died of toxicity. At present, 14 patients are alive with a median survival time of 23 months from study entry: four are in first CR, three are in second CR, and one is in fourth CR. Six patients are alive with disease. Eighteen patients (56%) died: 17 of disease and one of toxicity. Transplantation-related mortality was 3.1%. The relapse or progression disease rate was 84.4%. The 3-year overall survival rate is 20% and the 3-year disease-free survival rate is 12%.
CONCLUSION: HDCT combined with surgery is feasible and can induce CR in a large portion of patients. Two points, however, need to be considered: only patients who are chemosensitive to induction treatment can obtain CR after HDCT, and the length of remission is short, because most patients relapse. Thus novel strategies are needed to maintain the remission status or to treat patients who do not respond to induction treatment.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al.
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
Ann. Onc.,
October 1, 2006;
17(10):
1479 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ferrari, S. Smeland, M. Mercuri, F. Bertoni, A. Longhi, P. Ruggieri, T. A. Alvegard, P. Picci, R. Capanna, G. Bernini, et al.
Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups
J. Clin. Oncol.,
December 1, 2005;
23(34):
8845 - 8852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton
Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma
Clin. Cancer Res.,
October 1, 2005;
11(19):
6895 - 6900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Perissinotto, G. Cavalloni, F. Leone, V. Fonsato, S. Mitola, G. Grignani, N. Surrenti, D. Sangiolo, F. Bussolino, W. Piacibello, et al.
Involvement of Chemokine Receptor 4/Stromal Cell-Derived Factor 1 System during Osteosarcoma Tumor Progression
Clin. Cancer Res.,
January 15, 2005;
11(2):
490 - 497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
